Alizé Pharma is a group of privately held biopharmaceutical companies specialized in the development of innovative biopharmaceutical drugs, proteins and peptides, for the treatment of metabolic diseases and rare diseases.
AZP531. A peptide analog to Unacylated Ghrelin (UAG) intended to be developed as a treatment for the Prader Willi syndrome and Type 2 Diabetes.
Status: clinical Phase I-Unpartnered.
ASPAREC® is a PEGylated recombinant Erwinia chrysantemi-derived L-asparaginase, to be developed for the treatment of Acute Lymphoblastic Leukemia (ALL) in patients with hypersensitivity to E. coli-derived L-asparaginase.
Status: Phase I, partnered (EUSA Pharma)